JFG Wealth Management LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

JFG Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,510 shares of the company’s stock, valued at approximately $220,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Seaview Investment Managers LLC purchased a new position in CRISPR Therapeutics in the 4th quarter valued at approximately $275,000. Mach 1 Financial Group LLC purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $441,000. Brighton Jones LLC acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth $216,000. Atria Wealth Solutions Inc. boosted its position in shares of CRISPR Therapeutics by 14.8% in the 4th quarter. Atria Wealth Solutions Inc. now owns 6,423 shares of the company’s stock worth $402,000 after buying an additional 829 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at about $77,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on CRSP shares. Wolfe Research assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Chardan Capital raised their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Citigroup lifted their price target on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Stock Up 1.5 %

Shares of CRSP traded up $0.83 during mid-day trading on Thursday, reaching $54.64. 299,554 shares of the stock traded hands, compared to its average volume of 1,766,754. The stock has a fifty day simple moving average of $68.93 and a 200 day simple moving average of $64.15. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of -27.77 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. The business’s quarterly revenue was up 3253.3% on a year-over-year basis. During the same period last year, the firm earned ($1.41) EPS. On average, equities research analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at approximately $15,057,615.72. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at approximately $15,057,615.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Raju Prasad sold 3,524 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now directly owns 6,476 shares of the company’s stock, valued at approximately $470,740.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,992 shares of company stock valued at $6,132,335. 4.10% of the stock is currently owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.